Expression of cyclooxygenase-2 in endometrial adenocarcinoma

Gokhan Kilic, B. Gurates, J. Garon, H. Kang, B. Arun, C. E. Lampley, R. Kurzel, R. Ashfaq

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Studies have shown that COX-2 is up-regulated in several epithelial carcinomas. In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium. Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2. A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse. Statistical analysis was performed using the Kruskal-Wallis test; differences between groups were evaluated using the Fisher's Exact Test. We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1%) with endometrial adenocarcinoma: in contrast only one of 13 (7.7%) control patients demonstrated increased COX-2 expression (p ≤ 0.05). Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively). In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type. This may provide an avenue for chemoprevention of endometrial adenocarcinoma. In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma. Further studies are required to investigate the role of COX-2 expression in carcinogenesis.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume26
Issue number3
StatePublished - 2005
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Adenocarcinoma
Endometrium
Uterine Prolapse
Chemoprevention
Endometrial Neoplasms
Carcinogenesis
Immunohistochemistry
Carcinoma
Control Groups

Keywords

  • Aromatase
  • COX-2
  • Endometrial cancer
  • Immunohistochemistry

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Kilic, G., Gurates, B., Garon, J., Kang, H., Arun, B., Lampley, C. E., ... Ashfaq, R. (2005). Expression of cyclooxygenase-2 in endometrial adenocarcinoma. European Journal of Gynaecological Oncology, 26(3), 271-274.

Expression of cyclooxygenase-2 in endometrial adenocarcinoma. / Kilic, Gokhan; Gurates, B.; Garon, J.; Kang, H.; Arun, B.; Lampley, C. E.; Kurzel, R.; Ashfaq, R.

In: European Journal of Gynaecological Oncology, Vol. 26, No. 3, 2005, p. 271-274.

Research output: Contribution to journalArticle

Kilic, G, Gurates, B, Garon, J, Kang, H, Arun, B, Lampley, CE, Kurzel, R & Ashfaq, R 2005, 'Expression of cyclooxygenase-2 in endometrial adenocarcinoma', European Journal of Gynaecological Oncology, vol. 26, no. 3, pp. 271-274.
Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE et al. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. European Journal of Gynaecological Oncology. 2005;26(3):271-274.
Kilic, Gokhan ; Gurates, B. ; Garon, J. ; Kang, H. ; Arun, B. ; Lampley, C. E. ; Kurzel, R. ; Ashfaq, R. / Expression of cyclooxygenase-2 in endometrial adenocarcinoma. In: European Journal of Gynaecological Oncology. 2005 ; Vol. 26, No. 3. pp. 271-274.
@article{97837fa4e74944a0abe84a78ca026046,
title = "Expression of cyclooxygenase-2 in endometrial adenocarcinoma",
abstract = "Studies have shown that COX-2 is up-regulated in several epithelial carcinomas. In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium. Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2. A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse. Statistical analysis was performed using the Kruskal-Wallis test; differences between groups were evaluated using the Fisher's Exact Test. We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1{\%}) with endometrial adenocarcinoma: in contrast only one of 13 (7.7{\%}) control patients demonstrated increased COX-2 expression (p ≤ 0.05). Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively). In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type. This may provide an avenue for chemoprevention of endometrial adenocarcinoma. In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma. Further studies are required to investigate the role of COX-2 expression in carcinogenesis.",
keywords = "Aromatase, COX-2, Endometrial cancer, Immunohistochemistry",
author = "Gokhan Kilic and B. Gurates and J. Garon and H. Kang and B. Arun and Lampley, {C. E.} and R. Kurzel and R. Ashfaq",
year = "2005",
language = "English (US)",
volume = "26",
pages = "271--274",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of cyclooxygenase-2 in endometrial adenocarcinoma

AU - Kilic, Gokhan

AU - Gurates, B.

AU - Garon, J.

AU - Kang, H.

AU - Arun, B.

AU - Lampley, C. E.

AU - Kurzel, R.

AU - Ashfaq, R.

PY - 2005

Y1 - 2005

N2 - Studies have shown that COX-2 is up-regulated in several epithelial carcinomas. In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium. Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2. A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse. Statistical analysis was performed using the Kruskal-Wallis test; differences between groups were evaluated using the Fisher's Exact Test. We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1%) with endometrial adenocarcinoma: in contrast only one of 13 (7.7%) control patients demonstrated increased COX-2 expression (p ≤ 0.05). Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively). In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type. This may provide an avenue for chemoprevention of endometrial adenocarcinoma. In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma. Further studies are required to investigate the role of COX-2 expression in carcinogenesis.

AB - Studies have shown that COX-2 is up-regulated in several epithelial carcinomas. In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium. Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2. A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse. Statistical analysis was performed using the Kruskal-Wallis test; differences between groups were evaluated using the Fisher's Exact Test. We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1%) with endometrial adenocarcinoma: in contrast only one of 13 (7.7%) control patients demonstrated increased COX-2 expression (p ≤ 0.05). Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively). In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type. This may provide an avenue for chemoprevention of endometrial adenocarcinoma. In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma. Further studies are required to investigate the role of COX-2 expression in carcinogenesis.

KW - Aromatase

KW - COX-2

KW - Endometrial cancer

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=21144457702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144457702&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 271

EP - 274

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -